Clinical trials: Cephalalgia
Migraine Disorders
Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients
To confirm the combination rationale for the combination of ASA + paracetamol + caffeine compared with the combination of ASA + paracetamol and the individual substances ASA, paracetamol, caffeine, and placebo administered orally…
- Trial name
- NCT02183688
- Testing
- Low dose ASA, High dose ASA, Low dose paracetamol
- Volunteers
- 1,889 people
- Sponsor
- Boehringer Ingelheim
Cerebrovascular Accident
Headache Study to Compare Aggrenox Full Dose and Reduced Dose
Tolerability of a four weeks treatment with Aggrenox® modified release capsules b.i.d, compared to reduced dose during the first two weeks of treatment in a double-blind, randomized controlled parallel group comparison trial…
- Trial name
- NCT00274586
- Testing
- Aggrenox® modified release capsules
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- Boehringer Ingelheim
Episodic Cluster Headache
A Study Of Galcanezumab In Participants With Episodic Cluster Headache
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as Galcanezumab in participants with episodic cluster headaches.
- Trial name
- NCT02397473
- Testing
- Galcanezumab
- Where
- 47 sites in United States, Belgium and 10 more
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Migraine
Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine
The study is being conducted to explore the safety and effectiveness of a new chemical entity, BGC20-1531, in subjects with a history of migraine.
- Trial name
- NCT00888680
- Testing
- BGC20-1531, Lactose
- Where
- 4 sites in Denmark, Norway and 1 more
- Sponsor
- Boston Scientific Corporation
Migraine
Study of Oral Atogepant Tablets to Assess Change in Disease Activity in Adult Japanese Participants With Episodic Migraine
A migraine is a moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms.
- Trial name
- JPN PIVOTAL (NCT05861427)
- Testing
- Atogepant
- Where
- 48 sites in Japan
- Volunteers
- 524 people
- Sponsor
- AbbVie
Migraine
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study
The main purpose of this study is to evaluate the efficacy of the study drug known as galcanezumab in participants with episodic migraine.
- Trial name
- EVOLVE-1 (NCT02614183)
- Testing
- Galcanezumab
- Where
- 95 sites in United States, Canada and 1 more
- Volunteers
- 862 people
- Sponsor
- Eli Lilly and Company
Migraine Headaches
A Study of the Efficacy of RWJ-333369 in the Prevention of Migraine
The purpose of this study is to evaluate whether RWJ-333369 is a safe and effective treatment in reducing the number of migraine headaches when added to a person's usual medications for acute migraine headache relief.
- Trial name
- NCT00109083
- Testing
- RWJ-333369
- Where
- 25 sites in United States
- Volunteers
- 300 people
- Sponsor
- SK Life Science, Inc.
Cluster Headache
Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache
Ketamine has been used clinically IV in a very safe manner by a very small number of clinicians, to treat migraines and CH, and various other rarer pain disorders, including mixed headache and neuropathic pain clinical syndromes.
- Trial name
- NCT04179266
- Testing
- Ketamine
- Where
- Denmark
- Volunteers
- 23 people
- Sponsor
- CCH Pharmaceuticals
Headache
SPG Blocks for Headaches
This will be a single-center, open-label clinical trial comparing sphenopalatine ganglion blocks to standard intravenous therapy for patients who come to the emergency department for a headache.
- Trial name
- NCT04255420
- Testing
- SPG Block, Standard IV Treatment
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Kendall Healthcare Group, Ltd.
Migraine, Photophobia
An Efficacy Study of a Single Dose Treatment of PRO-513 for Subjects Suffering a Migraine Attack
The purpose of the study is to show the efficacy of a single dose of PRO-513 for treating subjects suffering moderate pain form a migraine attack, with or without aura.
- Conditions
- Migraine, Photophobia, Phonophobia
- Trial name
- NCT00330850
- Testing
- PRO-513
- Where
- 16 sites in United States
- Volunteers
- 650 people
- Sponsor
- ProEthic Pharmaceuticals
Migraine
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
- Trial name
- UBR Prodrome (NCT04492020)
- Testing
- Ubrogepant 100 mg
- Where
- 73 sites in United States
- Volunteers
- 518 people
- Sponsor
- AbbVie
Chronic Migraine, Headache
Open Label, 6-month Study for High Frequency and Chronic Migraine,
This is a prospective, multi-center, unblinded study in patients with migraine (≥ 8 MMDs/month) requiring preventive treatment. Enrolled patients will receive DAX administered subcutaneously using an established, published…
- Trial name
- NCT06133491
- Testing
- Daxibotulinumtonix A
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Ki Health Partners. LLC
Migraine Headache
Zomig - Treatment of Acute Migraine Headache in Adolescents
The purpose of this study is to investigate if Zomig® Nasal Spray will help children (age 12-17 years) with migraine headaches feel better.
- Trial name
- TEENZ (NCT01211145)
- Testing
- Zolmitriptan
- Where
- 74 sites in United States, Estonia and 6 more
- Volunteers
- 1,653 people
- Sponsor
- AstraZeneca
Migraine
A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack
The purpose of this research study is to evaluate an investigational auto-injector system for delivering sumatriptan under the skin for a single migraine attack.
- Trial name
- NCT00510419
- Testing
- "Investigational"Auto-injector (sumatriptan succinate)
- Where
- 10 sites in United States
- Volunteers
- 73 people
- Sponsor
- Pfizer
Migraine Disorders
A Long-term Efficacy, Safety, and Tolerability Study of BOTOX® in Patients With Chronic Migraine
This open-label study will assess the long-term efficacy, safety, and tolerability of onabotulinumtoxinA administered for prophylaxis of headaches in patients with chronic migraine.
- Trial name
- NCT01516892
- Testing
- onabotulinumtoxinA
- Where
- 32 sites in United States, Australia and 1 more
- Volunteers
- 716 people
- Sponsor
- Allergan
Migraine, Ketogenic Dieting
Th Effect of Ketogenic Metabolic Nutritional Pattern on High-frequency Episodic Migraine (EMIKETO)
The study aims to investigate the impact of 2 nutritional patterns on high-frequency episodic migraine. Subjects enrolled will be randomized in two arms: a) very-low-calorie-ketogenic-diet (VLCKD), b) hypocaloric balanced non…
- Conditions
- Migraine, Ketogenic Dieting, Weight Loss, Overweight
- Trial name
- EMIKETO (NCT04360148)
- Testing
- very-low-calorie-ketogenic-diet, hypocaloric-balanced-diet
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- New Penta SRL
Migraine Disorders, Migraine, Acute
TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults
Study TRX109011/TRX109013, A Randomized, Double-blind, Double-dummy, Placebo-controlled, Crossover Study to Evaluate the Efficacy of TREXIMET® (Sumatriptan + Naproxen Sodium) versus Butalbital-containing Combination Medications…
- Trial name
- NCT00573170
- Testing
- TREXIMET®, Butalbital-containing Combination Medications (BCM)
- Where
- 107 sites in United States
- Volunteers
- 375 people
- Sponsor
- GlaxoSmithKline
Chronic Migraine
Assessment of LBR-101 In Chronic Migraine
The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in patients with chronic migraine.
- Trial name
- NCT02021773
- Testing
- LBR-101 High Dose, LBR-101 Low Dose
- Where
- 57 sites in United States
- Volunteers
- 264 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine
Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine
This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treatment of migraine.
- Trial name
- NCT06603623
- Testing
- BHV-2100
- Where
- 60 sites in United States
- Volunteers
- 647 people
- Sponsor
- Biohaven Therapeutics Ltd.
Migraine
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD1910, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.
- Trial name
- NCT04197349
- Testing
- ALD1910, Sumatriptan
- Where
- Australia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S